Cellectar Biosciences (CLRB) Total Non-Current Liabilities (2010 - 2025)
Cellectar Biosciences (CLRB) posted Total Non-Current Liabilities of $5.2 million for Q3 2025, down 15.73% sequentially from $6.2 million in Q2 2025, and down 74.7% YoY from $20.7 million in Q3 2024.
Cellectar Biosciences (CLRB) Total Non-Current Liabilities (2010 - 2025) Analysis & Trends
Cellectar Biosciences has reported Total Non-Current Liabilities for 13 years, with the latest figure at $5.2 million in Q3 2025.
- Quarterly Total Non-Current Liabilities fell 74.7% year-over-year to $5.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $5.2 million (down 74.7% YoY) and the FY2020 annual result came in at $301740.0, down 28.44% from the prior year.
- Total Non-Current Liabilities slipped to $5.2 million in Q3 2025 per CLRB's latest filing, from $6.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $29.0 million in Q1 2024 and troughed at $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 9.32 Bn |
| 10 | Cellectar Biosciences | 6.76 Mn | 6.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.25 Mn |
| Jun 30, 2025 | 6.23 Mn |
| Mar 31, 2025 | 6.41 Mn |
| Sep 30, 2024 | 20.75 Mn |
| Mar 31, 2024 | 29.03 Mn |
| Dec 31, 2020 | 301,740.00 |
| Sep 30, 2020 | 517,375.00 |
| Jun 30, 2020 | 547,534.00 |
| Mar 31, 2020 | 392,950.00 |
| Dec 31, 2019 | 421,644.00 |
| Sep 30, 2019 | 449,632.00 |
| Jun 30, 2019 | 476,247.00 |
| Mar 31, 2019 | 502,207.00 |
| Dec 31, 2018 | 170,999.00 |
| Jun 30, 2018 | 568.00 |
| Mar 31, 2018 | 1,402.00 |
| Dec 31, 2017 | 2,213.00 |
| Sep 30, 2017 | 146,043.00 |
| Jun 30, 2017 | 147,923.00 |
| Mar 31, 2017 | 149,887.00 |